TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.


Options:
A: Arm Label: Adderall Extended Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Arm Label: Adderall Immediate Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Intervention Type: DRUG; Name: Adderall ® Immediate Release; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First | Intervention Type: DRUG; Name: Adderall XR ®; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First
B: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients
Brief Summary: We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF.

Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).


Options:
A: Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate (4PBA), Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate (4PBA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: miglustat | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: miglustat; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.


Options:
A: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
D: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.


Options:
A: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: Carboplatin plus PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pegylated Lipoxomal Doxorubicin (PLD) | Arm Label: Trabectedin plus PLD; Type: EXPERIMENTAL; Interventions: Drug: Pegylated Lipoxomal Doxorubicin (PLD), Drug: Trabectedin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin plus PLD | Intervention Type: DRUG; Name: Pegylated Lipoxomal Doxorubicin (PLD); Assigned to Arm(s): Carboplatin plus PLD, Trabectedin plus PLD | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin plus PLD
C: Arm Label: Paclitaxel/Carboplatin/Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin
D: Arm Label: Bevacizumab+TC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: TC:paclitaxel + carboplatin | Arm Label: TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: TC:paclitaxel + carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab+TC | Intervention Type: DRUG; Name: TC:paclitaxel + carboplatin; Assigned to Arm(s): Bevacizumab+TC, TC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
B: Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
C: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
D: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: CLOSE guided PVI and insertable cardiac monitor; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation; Assigned to Arm(s): CLOSE guided PVI and insertable cardiac monitor
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
D: Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: AIT: aerobic interval training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic interval training | Arm Label: MIT, moderate intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: moderate intensity training | Arm Label: Recommendation of regular exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendation of regular exercise | Intervention Type: BEHAVIORAL; Name: Aerobic interval training; Assigned to Arm(s): AIT: aerobic interval training | Intervention Type: BEHAVIORAL; Name: moderate intensity training; Assigned to Arm(s): MIT, moderate intensity training | Intervention Type: BEHAVIORAL; Name: Recommendation of regular exercise; Assigned to Arm(s): Recommendation of regular exercise
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise - Continuous Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Continuous Walking | Arm Label: Exercise - Interval Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise Training - Interval Walking; Assigned to Arm(s): Exercise - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise - Continuous Walking; Assigned to Arm(s): Exercise - Continuous Walking
D: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: Podcasting + mobile media; Type: EXPERIMENTAL; Interventions: Behavioral: Podcasting + mobile media | Arm Label: Podcasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Podcasting + mobile media | Intervention Type: BEHAVIORAL; Name: Podcasting + mobile media; Assigned to Arm(s): Podcasting, Podcasting + mobile media
B: Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight.; Assigned to Arm(s): N/A
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
B: Arm Label: diet following American Diabetes Association guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: diet following ADA guidelines | Arm Label: vegan diet; Type: EXPERIMENTAL; Interventions: Other: vegan diet | Intervention Type: OTHER; Name: vegan diet; Assigned to Arm(s): vegan diet | Intervention Type: OTHER; Name: diet following ADA guidelines; Assigned to Arm(s): diet following American Diabetes Association guidelines
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
D: Arm Label: Eco-Atkins diet; Type: EXPERIMENTAL; Interventions: Other: Eco-Atkins diet (high vegetable protein and vegetable fat) | Arm Label: NCEP diet; Type: ACTIVE_COMPARATOR; Interventions: Other: NCEP diet | Intervention Type: OTHER; Name: Eco-Atkins diet (high vegetable protein and vegetable fat); Assigned to Arm(s): Eco-Atkins diet | Intervention Type: OTHER; Name: NCEP diet; Assigned to Arm(s): NCEP diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Balance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Behavioral Weight Loss Program; Assigned to Arm(s): Lifestyle Balance
B: Arm Label: Lifestyle intervention to increase physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: lifestyle intervention to increase physical activity | Arm Label: waiting control group; Type: NO_INTERVENTION; Interventions: Behavioral: lifestyle intervention to increase physical activity | Intervention Type: BEHAVIORAL; Name: lifestyle intervention to increase physical activity; Assigned to Arm(s): Lifestyle intervention to increase physical activity, waiting control group
C: Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: D